SK Biopharmaceuticals (326030 KS): A Promising Play on Central Nervous System Disorders
SKBP's independently developed and marketed drug Xcopri has the potential to reach peak revenue of $1.5 billion in 2027. The company targets to...
574 Views
Para IV Winners and Losers - August 2018
This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...
373 Views
Para IV Winners and Losers - June 2018
This month’s Para IV developments suggest that there is likely to be benefit to Baxter International Inc (BAX US) on Premix Precedex (4mc/ml), Endo...
471 Views
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
3.3k Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
597 Views